Skip to main content
Premium Trial:

Request an Annual Quote

FinchLab 3.2, MagNA Pure LC 2.0

Premium
Geospiza has released FinchLab 3.2.The new version of the genetic-analysis workflow- and data-management system provides new analytical capabilities, including secondary analysis for second-generation sequencing.
 
According to the company, FinchLab 3.2 integrates “best of breed” algorithms to characterize data sets for experiments such as tag profiling.
 

 
Roche Applied Science has launched the MagNA Pure LC 2.0 System, an upgraded version of its nucleic acid-purification technology that is applicable to PCR, RT-PCR, sequencing, and microarrays, the company said.
 
New features in the MagNA Pure LC 2.0 include “a complete redesign” of the system’s housing, optimized handling, an integrated computer and LCD monitor with touch screen, new software, and LIMS/network compatibility.
 
In addition, the system’s error handling has been “significantly improved,” Roche said.
 
The system is designed to automate nucleic acid purification and PCR setup in the medium- to high-throughput range, and can process up to 32 samples at a time. Roche said it takes 52 to 180 minutes to purify 32 samples, depending on the application.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.